Polygenic Risk Score Testing Market

Polygenic Risk Score Testing Market Summary:

According to Transpire Insight, a detailed research report on the market reflects that the clinical applications segment dominates the Polygenic Risk Score Testing Market, accounting for approximately 58% of the total share worldwide. Myriad Genetics leads the market with approximately (around USD 765 million) in annual revenue and an estimated 15-19% market share, making it a leading contributor to market development, innovation, advanced polygenic risk score testing solutions, expanding genomic testing capabilities, and growth dynamics.

Market Snapshot

• Market Value (2025): USD 1.02 Billion.
• Expected Market Value (2026): USD 1.24 Billion.
• Estimated Market Value (2033): USD 5.18 Billion.
• Forecast CAGR (2026-2033): 22.67%
• Leading Region in 2025: North America
• Second-largest Region: Europe
• Fastest Growing Region: Asia Pacific

Introduction

The polygenic risk score testing market includes the service of measuring an individual's genetic predisposition toward the risk of developing complex and multi-factorial diseases in the commercial, clinical, and bioinformatics sectors. Instead of testing a rare mutation like a single-gene test, the polygenic risk score adds up the contributions of thousands to millions of genetic variants i.e. Single Nucleotide Polymorphisms (SNPs) present in the person's genome. This score gives an idea about the individual’s risk of developing a disease such as cardiovascular disease, Type II diabetes, or some common cancers. Polygenic Risk Score a number that estimates an individual's genetic predisposition to a particular complex trait or disease, such as heart diseases, diabetes, or cancer by combining the tiny, additive effects of a number of genetic factors (usually SNPs, single-nucleotide polymorphisms identified through genome-wide association studies). Testing for polygenic risk scores is an important part of precision medicine and preventive healthcare because it enables early risk stratification for complex diseases even before clinical symptoms appear. It facilitates personalized prevention by allowing health practitioners to adapt lifestyle modification plans, screening timelines, and methods of preventive treatment depending on the patient’s genetic predisposition. Further, PRS testing can lead to more efficient clinical trials by assisting in discovery of high-risk patients for targeted recruitment and making better use of resources in research. Contrary to single gene testing, polygenic risk scores evaluate the impact of thousands of genetic variants, providing a better assessment of the predisposition to diseases.

For instance:-Precision medicine investments and risk assessments for chronic diseases are driving the growth of the polygenic risk score (PRS) testing industry, but Russia's sector is still relatively isolated because of international sanctions and localized domestic bio-security regulations.

Market Highlights: -

• North America is expected to grow at a rapid CAGR in the Polygenic Risk Score Testing Market by holding roughly 41% of the share during the forecast period. 
• Europe is anticipated to hold roughly 28% share of the Polygenic Risk Score Testing Market over the predicted timeframe. 
• Asia Pacific is anticipated to hold roughly 18% share of the Polygenic Risk Score Testing Market over the predicted timeframe. 
• By test type, the Cancer Risk Testing segment dominated the market and holds nearly 35% share in 2025 and is projected to grow at a substantial CAGR during the forecast period. 
• By end user, the Hospitals segment dominated the market and holds nearly 44% share in 2025 and is projected to grow at a substantial CAGR during the forecast period. 
• By application, the Precision Medicine segment dominated the market and holds nearly 32% share in 2025 and is projected to grow at a substantial CAGR during the forecast period. 
• National Health Service (NHS): The United Kingdom (UK) is taking steps to push genomic medicine ahead through NHS Genomic Medicine Service and other initiatives to encourage population health. Utilization of polygenic risk scores is being investigated in order to make advanced predictions and preventive care more efficient. Such steps further facilitate the increased use of polygenic risk score testing and promote the resurgence of the Polygenic Risk Score Testing Market.

How is Technology Driving Growth in the Polygenic Risk Score Testing Market?

The Polygenic Risk Score Testing Market is being affected by the advancements in technologies. The Next-Generation Sequencing (NGS) technique has played an important role in decreasing the cost of genomic testing and gaining access to high-density genetic data. The use of artificial intelligence and machine learning makes it easier to analyze millions of genetic variants and develop risk models effectively. There are many biobanks and genomic databases, which help researchers validate polygenic risk scores in different populations. As a result of multimonic integration and digital health platforms, experts are able to improve disease risk assessment by combining genetic data with other biological and clinical data.

Market Drivers

The growth of Polygenic Risk Score Testing Market is attributed to the growing occurrence of chronic conditions, growing use of the precision medicine and rising requirement for the early disease-risk assessment. Technological development in next-generational sequencing, artificial intelligence and bioinformatics is boosting the accuracy of testing and its clinical interpretation. The growth of genomic libraries and initiatives of population-size sequencing is also contributing to the effectiveness of risk prediction in different populations. Also rising health awareness and better availability of genetic services to consumers are making polygenic risk score testing more available to consumers. Polygenic risk score testing provides significant advantages by facilitating the early prediction of the risk of developing complex conditions, such as cardiovascular diseases, diabetes, and some tumors, before the onset of symptoms. The information obtained from this analysis allows healthcare practitioners to adopt proactive approaches in terms of patient management by designing personalized screening, prevention, and lifestyle recommendations based on an individual's genetic predisposition towards certain conditions. PRS enables more effective patient stratification and enhances the efficacy of clinical trials through targeted research. Unlike traditional single-gene testing methods, polygenic risk scores take into account several gene mutations at a time and hence can be applied in larger patient populations.

For Instance: -

• The expansion of underrepresented population datasets, AI-driven genomic interpretation, and chronic disease risk stratification are the main areas of investment in the polygenic risk score (PRS) testing market. These factors are essential for enhancing predictive accuracy in various places such as South Africa.
• The United States and North America dominate the polygenic risk score (PRS) testing industry due to significant institutional and venture capital expenditures in precision medicine, AI-powered genomic platforms, and chronic disease risk stratification.

Restrain

Various challenges encountered by the Polygenic Risk Score Testing Market include a lack of clinical standardization, regulatory uncertainty, concerns with genetic privacy, the threat of discrimination, the use of models with ancestral bias, and high testing costs with no guaranteed reimbursement. Furthermore, differences in clinical effectiveness and interpretations between populations may cause adoption issues.

Analysis of Prices and Consumer Behaviour 

Since genotyping services account for the largest market share (38.5% of the overall market), polygenic risk score testing is expected to remain the leading segment. The cost-effectiveness, ease of scale, and extensive experience of genotyping services make them the most widely employed form of genetic variant analysis in both clinical and scientific settings for disease risk assessment. The complexity of the testing, genomic analysis, need for data interpretation and clinical validation impact the price of polygenic risk score testing based on genotyping; advanced forms of the testing are generally sold at a higher price point than basic services. It is estimated that more than 62.2% of the total volume of polygenic risk score testing is performed using blood samples. The scale can be explained by the fact that blood-based genomic tests have many advantages in the clinical and research environments due high value DNA and established infrastructure of biobanks. Cardiovascular disease segment makes up around 34.5% of the market. The purchasing behavior of healthcare providers shows that the main factors affecting the adoption of polygenic risk score testing are precision, clinical validity, accuracy of genomic data, and reliable interpretation. Moreover, another 33% may opt for bulk purchasing or long-term contracts provided that these arrangements help in cost-saving and ensuring a stable testing capability, but no particular percentage of this purchasing behavior has been officially verified.

Who are the Key Players in the Barcode Printers Market and how do they compete?

Competitiveness in the market for polygenic risk score testing relies on organizations that focus on genomics innovations, precision medicine solutions, clinical applications, and establishing healthcare networks ly. Instead of competing primarily on price, they use advanced genetic testing platforms, data analytics, clinical interpretation, and electronic health records integration, which leads to continuous progress of innovation and assists in reaching higher accuracy in terms of disease risk evaluation and personalized medicine.

Through development of genomic testing services, bioinformatics platforms, and risk assessment technologies, Myriad Genetics strengthens its status on the market. By providing effective testing services for consumers, companies distinguish themselves from competitors in terms of high-quality services, used in the fields of oncology, cardiovascular health, and preventive medicine.

Top Companies in the Polygenic Risk Score Testing Market

1. Illumina
2. Thermo Fisher Scientific
3. 23andMe
4. Myriad Genetics
5. Quest Diagnostics
6. Labcorp
7. Color Health
8. Fulgent Genetics
9. Invitae
10. Natera
11. SOPHiA GENETICS
12. Tempus AI
13. Genomics plc
14. Helix
15. BGI Genomics

Market Segmentation

The Polygenic Risk Score Testing Market share is divided into five categories: By test type, technology, end user, application and distribution channel.

The Cancer Risk Testing dominated the market, accounting for nearly 35% in 2025 and is expected to rise at a significant CAGR during the forecast period.

The Polygenic Risk Score Testing Market is segmented by test type Cardiovascular Disease Risk Testing, Cancer Risk Testing, Diabetes Risk Testing, Neurological Disorder Risk Testing, Autoimmune Disease Risk Testing, Rare Disease Risk Testing, Multi-disease Risk Testing, Others. Among these, the Cancer Risk Testing segment dominated the market, accounting for nearly 35% in 2025 and expected to increase at a significant CAGR during the forecast period. The market was dominated by cancer risk testing, which accounted for almost 35% in 2025 and is predicted to grow at a notable CAGR over the course of the forecast period. The rising incidence of cancer, the need for early risk assessment, and the growing use of precision medicine all contribute to this dominance. By enhancing personalized cancer susceptibility assessment and bolstering focused screening techniques, polygenic risk scores can supplement traditional criteria.

The Hospitals dominated the market, accounting for nearly 44% in 2025, and is expected to rise at a significant CAGR during the forecast period.

The Polygenic Risk Score Testing Market is segmented by end user into Hospitals, Diagnostic Laboratories, Research Institutes, Biotechnology Companies, Pharmaceutical Companies, Direct-to-Consumer Testing, Others. Among these, the Hospitals segment dominated the market, accounting for nearly 44% in 2025 and expected to increase at a significant CAGR during the forecast period. Hospitals accounted for almost 44% of the market in 2025 and are predicted to grow at a substantial CAGR over the course of the forecast period. Hospitals' sophisticated genomic infrastructure, the increasing use of precision medicine, the growing integration of genetic risk assessment into clinical workflows, and the growing need for early disease-risk stratification and individualized preventative therapy are all factors contributing to this dominance.

The Precision Medicine dominated the market, accounting for nearly 32% in 2025 and is expected to rise at a significant CAGR during the forecast period.

The Polygenic Risk Score Testing Market is segmented by application into Preventive Healthcare, Precision Medicine, Clinical Research, Drug Development, Population Screening, Genetic Counseling, Others. Among these, the Precision Medicine segment dominated the market, accounting for nearly 32% in 2025 and expected to increase at a significant CAGR during the forecast period. Precision medicine accounted for around 32% of the market in 2025 and is predicted to grow at a substantial CAGR over the course of the forecast period. Personalized healthcare is becoming more and more popular, genetic risk assessment is becoming more widely used, bioinformatics is developing, and polygenic risk scores are being used in more clinical settings for early identification, illness prevention, and tailored treatment plans.

Regional Segment Analysis of the Polygenic Risk Score Testing Market:

• North America (U.S., Canada, Mexico)  
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe) 
• Asia-Pacific (China, Japan, India, Rest of APAC) 
• South America (Brazil and the Rest of South America)  
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is the fastest-growing region in the Polygenic Risk Score Testing Market during the period, holding roughly 41% share.

North America is expected to grow at a rapid CAGR in the Polygenic Risk Score Testing Market holding roughly 41% share during the forecast period. Advanced genomics infrastructure, significant government-funded research, massive projects like All of Us, and the expanding use of precision medicine all contribute to North America's dominant position in the polygenic risk score testing market. Large genomic datasets, clinical PRS research, and broader integration of genetic risk assessment into preventative healthcare are all made possible by these causes.

Europe is expected to grow at a rapid CAGR in the Polygenic Risk Score Testing Market, holding roughly 28% of the share during the forecast period.

Europe is expected to grow at a rapid CAGR in the Polygenic Risk Score Testing Market holding roughly 28% share during the forecast period. The market for polygenic risk score testing is anticipated to increase significantly in Europe due to the expansion of PRS-based screening programs, population biobanks, improved genomic infrastructure, and precision medicine initiatives. The need for polygenic risk score testing is increasing throughout European nations due to expanding clinical research and the incorporation of genomic testing into healthcare systems.

Asia Pacific is the fastest-growing region in the Polygenic Risk Score Testing Market during the period, holding roughly 18% share.

Asia Pacific is the fastest-growing region in the Polygenic Risk Score Testing Market during the forecast period, holding roughly 18% share during the forecast period. The polygenic risk score testing market is anticipated to grow at the quickest rate in Asia Pacific due to increased genomic research, government-backed precision medicine programs, falling sequencing prices, and rising genetic testing use. Large population datasets and initiatives like Taiwan's Precision Medicine Initiative are bolstering clinical risk assessment and population-specific PRS development.

Strategies for Market Growth in Non-Leading Regions:

The use of highly efficient and valid polygenic risk score testing technologies will make it possible for small and medium-sized healthcare providers and genomic laboratories to develop non-leading areas. The establishment of local facilities for genomic testing and data analysis will lower the reliance on third-party testing services and raise the effectiveness of testing as a whole. The creation of strategic partnerships with the local healthcare providers, genetic testing laboratories, research institutions and biotech companies will lead to better penetration of the market for polygenic risk score testing providers. In order to boost the awareness level in the area of genomic testing, polygenic risk assessment, clinical interpretation, data quality and standardization of testing methods, several training programs and improvement of technical skills have to be implemented. Flexible financing forms, long-term agreements for testing and custom-made arrangements for genomic testing can help make polygenic risk score testing more affordable and widely used by healthcare organizations.

Future Market Trends for the Polygenic Risk Score Testing Market: -

1. Artificial Intelligence and Multi-Omics Integration: Innovative algorithms with multi-omic data (integrating genomics with transcriptomics and outside factors) are replacing one-dimensional DNA analysis, resulting in enhanced accuracy of predictions.
2. Emphasis on Ancestry: Scientists and businesses are ceasing to rely on previous Eurocentric databases and using instead a ancestry framework, thus correcting the bias towards non-European groups.
3. Incorporation into Clinical Processes and Information Systems: Healthcare systems are shifting from direct-to-consumer PRS to standardized EHR for routine medical risk assessment.
4. Insurance & Prevention Programs: Insurance companies of life and health are taking an opportunity to research and subsidize genetic risk analysis to motivate people to change their lifestyles.
5. Growth of the Asia-Pacific Region: The region shows the fastest development, which can be explained by the presence of digital healthcare systems, aging population, and significant investments in precision medicine.

Recent Development

• In March 2026: Foundation Medicine began using its FlexOMx Lab to introduce a Whole Genome Sequencing (WGS) Germline test for research purposes. This is an extension of the company’s genomics research activities into fields such as cardiometabolic, immunologic, and neurologic diseases beyond oncology. The solution assists in evaluating polygenic risk scores for disease susceptibility which advances genomics research, precision medicine, and the evolution of sophisticated polygenic risk scoring solutions in the Polygenic Risk Score Testing Market.
• In May 2026: Yourgene Health unveiled the Yourgene® Insight DPYD Assay, an enhanced pharmacogenetic test that detects DPYD alterations linked to DPD insufficiency and fluoropyrimidine-related side effects. The assay detects 19 variants, promoting personalized treatment decisions and enhancing precision genomics and pharmacogenomics. The initiative is part of larger progress made in the area of genomic testing within the genetic testing market.
• In July 2026: In a significant database update, the Polygenic Score Catalog (PGS Catalog) added 1,522 new polygenic scores, increasing access to standardized genomic scoring data and providing tools for the study and assessment of polygenic risk scores. This advancement supports the ongoing expansion and uptake of Polygenic Risk Score Testing solutions within the Polygenic Risk Score Testing Market by bolstering genomic research, clinical innovation, and precision medicine applications.

This study forecasts revenue at regional and country levels from 2020 to 2033. Transpire Insight has segmented the Polygenic Risk Score Testing Market based on the below-mentioned segments:

Polygenic Risk Score Testing Market, By Test Type

• Cardiovascular Disease Risk Testing
• Cancer Risk Testing
• Diabetes Risk Testing
• Neurological Disorder Risk Testing
• Autoimmune Disease Risk Testing
• Rare Disease Risk Testing
• Multi-disease Risk Testing
• Others

Polygenic Risk Score Testing Market, By Technology

• Genotyping
• Whole Genome Sequencing
• SNP Analysis
• AI-based Risk Modeling
• Bioinformatics Platforms
• Machine Learning Analytics
• Others

Polygenic Risk Score Testing Market, By End User

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Biotechnology Companies
• Pharmaceutical Companies
• Direct-to-Consumer Testing
• Others

Polygenic Risk Score Testing Market, By Application

• Preventive Healthcare
• Precision Medicine
• Clinical Research
• Drug Development
• Population Screening
• Genetic Counseling
• Others

Polygenic Risk Score Testing Market, By Distribution Channel

• Hospital Procurement
• Diagnostic Centers
• Online Genetic Testing Platforms
• Direct Sales
• Research Partnerships
• Others

Polygenic Risk Score Testing Market, By Regional Analysis

North America

• US 
• Canada 
• Mexico 

Europe

• Germany 
• UK 
• France 
• Italy 
• Spain 
• Russia 
• Rest of Europe 

Asia Pacific

• China 
• Japan 
• India 
• South Korea 
• Australia 
• Rest of Asia Pacific 

South America

• Brazil 
• Argentina 
• Rest of South America 

Middle East & Africa

• UAE 
• Saudi Arabia 
• Qatar 
• South Africa 
• Rest of the Middle East & Africa